aibio
Listings ·
Larimar Therapeutics holders approve raising authorized shares to 215,000,000
Authorized common stock rises from 115,000,000 to 215,000,000 shares, against 103,882,937 shares outstanding at the March 25, 2026 record date.
LRMR Larimar Therapeutics, Inc.
Larimar Therapeutics (LRMR) news LRMR offering and convertible notes news
Latest Larimar Therapeutics news
- Financings
Larimar launches $75.0 million stock offering, then prices $100,000,000
Largest stockholder Deerfield and some directors indicated interest in buying. The priced offering is 20,000,000 shares at $5.00, or $94,000,000 to the company before expenses.
- Financings
Larimar Therapeutics to exchange 2,500,000 common shares for Series A preferred stock
Larimar agreed with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2,500,000 common shares for 250,000 Series A convertible preferred shares. Each preferred share converts into 10 common shares, and closing is expected January 23, 2026.
- Financings
Larimar swaps 2,500,000 common shares for 250,000 Series A preferred with Blue Owl fund
Each share of Series A convertible preferred stock converts into 10 shares of common stock, subject to certain limitations. The exchange was expected to close on January 23, 2026.
- Financings
Larimar Therapeutics swaps Blue Owl fund's 2,500,000 shares for Series A convertible preferred
Larimar Therapeutics agreed to swap 2,500,000 common shares held by a Blue Owl fund for 250,000 Series A convertible preferred shares, each convertible into 10 common shares. The filing calls the preferred "toothless," and the holder can raise its conversion blocker to 19.99%.
Larimar Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $154.2 million | $73.3 million |
| Net income (loss) | -$165.7 million | -$80.6 million |
| Cash from operations | -$113.2 million | -$70.8 million |
| Cash and equivalents | $85.4 million | $33.2 million |
| Short-term investments | $51.4 million | $150.2 million |
Questions about Larimar Therapeutics
Has Larimar Therapeutics raised money recently?
Our latest story on this, dated Feb 25, 2026: "Larimar launches $75.0 million stock offering, then prices $100,000,000". The story links the filing or release it is based on. Read the story.
Has Larimar Therapeutics sold convertible notes?
Our latest story on this, dated Jan 22, 2026: "Larimar Therapeutics to exchange 2,500,000 common shares for Series A preferred stock". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Larimar Therapeutics?
Larimar Therapeutics, Inc. trades under the ticker LRMR on NASDAQ.
Where is Larimar Therapeutics listed?
Larimar Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:ZA71; LS:A2P5PP; LSX:A2P5PP.
What is the SEC CIK of Larimar Therapeutics?
The SEC Central Index Key (CIK) for Larimar Therapeutics, Inc. is 1374690. Its filings are on SEC EDGAR.
How many shares does Larimar Therapeutics have outstanding?
103,882,937 shares as of 2026-08-02, per the cover page of its 10-Q filed 2026-08-04.
Which country or territory is Larimar Therapeutics listed under?
Our directory records Larimar Therapeutics, Inc. under United States.
What does Larimar Therapeutics do?
Our directory classifies Larimar Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Larimar Therapeutics?
The ISIN recorded for Larimar Therapeutics, Inc. is US5171251003.
Does aibio.space cover Larimar Therapeutics?
aibio.space lists Larimar Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Larimar Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Larimar Therapeutics profitable?
Larimar Therapeutics, Inc. reported a net loss of $165.7 million for the fiscal year ended Dec 31, 2025, and used $113.2 million of cash in operations, per its annual report to the SEC.
How much does Larimar Therapeutics spend on research and development?
$154.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Larimar Therapeutics have?
$156.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Larimar Therapeutics (LRMR) stock news?
Our latest story on Larimar Therapeutics, dated May 19, 2026: "Larimar Therapeutics holders approve raising authorized shares to 215,000,000". Authorized common stock rises from 115,000,000 to 215,000,000 shares, against 103,882,937 shares outstanding at the March 25, 2026 record date. Source.
Investor discussion: Larimar Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.03,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.03,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Larimar Therapeutics, Inc.
- CIK
- 1374690
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- LRMR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Phone
- 844-511-9056
- Shares outstanding
- 103,882,937 as of 2026-08-02 (10-Q filed 2026-08-04)
- Former names
- ZAFGEN, INC.; ZAFGEN INC
Recent filings
Listing details
- Company
- Larimar Therapeutics, Inc.
- Ticker
- LRMR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US5171251003
- Other listed symbols
- GETTEX:ZA71; LS:A2P5PP; LSX:A2P5PP
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction